))
Ep 16. Pregnancy RSV Vaccine Update. Expert Guest: Professor Paul Heath.
Manage episode 468906789 series 3619057
内容由Dr Eliz Kilich and Dr Lydia Yarlott, Dr Eliz Kilich, and Dr Lydia Yarlott提供。所有播客内容（包括剧集、图形和播客描述）均由 Dr Eliz Kilich and Dr Lydia Yarlott, Dr Eliz Kilich, and Dr Lydia Yarlott 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Pregnancy RSV Vaccine Update. Expert Guest: Professor Paul Heath.
Join us for an update on the respiratory syncytial virus (RSV) vaccine given during pregnancy. Hear what the latest evidence is.
This vaccine protects babies against a common cause of bronchiolitis which can be severe in newborns.
The UK has made a decision to prevent against RSV with Abrysvo™, the maternal vaccine, manufactured by Pfizer. Previously the UK had been considering the use of Nirsevimab instead. This is an RSV monoclonal antibody for newborns (Beyfortus™, manufactured by Sanofi Pasteur). Both the vaccine and the antibody were recommended as safe and effective options in 2023 by the JCVI. After a cost-effectiveness analysis and financial tender by the Department of Health, a decision was made to move to Abrysvo™.
The maternal vaccine success was revealed following a study involving over 7000 pregnant women, published in early 2023, the MATISSE trial. They showed that the Abrysvo™ maternal vaccine is highly effective at preventing severe infection in babies up to 180 days after birth. Vaccination is approved from 28 weeks of pregnancy in the UK.
At the same time, the MELODY and HARMONIE trials showed the monoclonal antibody for babies Beyfortus™, currently unavailable in the UK, also effectively prevents RSV for up to 6 months after administration. This vaccine can be given to all babies anytime from birth.
We now we hear about what the evidence is now that the UK has been giving the vaccine since September 2024.
Tune in now.
16集单集
分享
